Protein‐Nanocaged Selenium Induces t(8;21) Leukemia Cell Differentiation via Epigenetic Regulation
Open Access
- 27 October 2023
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 10 (35) , e2300698
Abstract
The success of arsenic in degrading PML‐RARα oncoprotein illustrates the great anti‐leukemia value of inorganics. Inspired by this, the therapeutic effect of inorganic selenium on t(8; 21) leukemia is studied, which has shown promising anti‐cancer effects on solid tumors. A leukemia‐targeting selenium nanomedicine is rationally built with bioengineered protein nanocage and is demonstrated to be an effective epigenetic drug for inducing the differentiation of t(8;21) leukemia. The selenium drug significantly induces the differentiation of t(8;21) leukemia cells into more mature myeloid cells. Mechanistic analysis shows that the selenium is metabolized into bioactive forms in cells, which drives the degradation of the AML1‐ETO oncoprotein by inhibiting histone deacetylases activity, resulting in the regulation of AML1‐ETO target genes. The regulation results in a significant increase in the expression levels of myeloid differentiation transcription factors PU.1 and C/EBPα, and a significant decrease in the expression level of C‐KIT protein, a member of the type III receptor tyrosine kinase family. This study demonstrates that this protein‐nanocaged selenium is a potential therapeutic drug against t(8;21) leukemia through epigenetic regulation.Keywords
Funding Information
- National Basic Research Program of China (2022YFA1205801)
- National Natural Science Foundation of China (82122037, 81930050, 31900981)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2019093)
- China Postdoctoral Science Foundation (2021M703420)
This publication has 41 references indexed in Scilit:
- Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cellsEpigenetics, 2013
- Magnetoferritin nanoparticles for targeting and visualizing tumour tissuesNature Nanotechnology, 2012
- Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PMLScience, 2010
- Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivityLeukemia, 2007
- Leukemia targeting ligands isolated from phage display peptide librariesLeukemia, 2007
- Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivoBlood, 2006
- Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-κB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent mannerCell Death & Differentiation, 2006
- AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AMLBlood, 2006
- The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemiaBlood, 2003
- GENETICS OF MYELOID LEUKEMIASAnnual Review of Genomics and Human Genetics, 2002